Empower Clinics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Vancouver, bc / accesswire / august 18, 2023 / empower clinics inc (cse:epw)(otc pink:epwcf) ("empower" or the "company") an integrated healthcare company with a developing research and clinical trials division announces various corporate updates. cease trade order on august 15th, 2023 the british columbia securities commission ("bcsc") issued a bulletin announcing empower is suspended pursuant to cse policy 3.

Vancouver, bc / accesswire / august 15, 2023 / empower clinics inc. ("empower" or the "company") (cse:epw)(otc pink:epwcf), is pleased to announce that it has closed a second tranche private placement of units of the company (the "units"), pursuant to which the company issued 1,625,000 units at a price of $0.04 per unit (the "offering price") for aggregate gross proceeds of $65,000 (the "offering"). each unit is comprised of one common share of the company (a "common share") and one common share purchase warrant (a "warrant"), with each warrant exercisable to acquire one common share (a "warrant share") at a price of $0.05 per warrant share for a period of 24 months from the closing of the offering.

Vancouver, bc / accesswire / august 9, 2023 / empower clinics inc. ("empower" or the "company") (cse:epw)(otc pink:epwcf), is pleased to announce that it has closed a first tranche private placement of units of the company (the "units"), pursuant to which the company issued 6,016,250 units at a price of $0.04 per unit (the "offering price") for aggregate gross proceeds of $240,250 (the "offering"). each unit is comprised of one common share of the company (a "common share") and one common share purchase warrant (a "warrant"), with each warrant exercisable to acquire one common share (a "warrant share") at a price of $0.05 per warrant share for a period of 24 months from the closing of the offering.

Vancouver bc / accesswire / august 1, 2023 / empower clinics inc. (cse:epw)(otc pink:epwcf) ("empower" or the "company") announces today, after a strategic review, the company has determined that it intends to complete a direct spin out of a wholly owned subsidiary of the company ("subco") and vend in a healthcare artificial intelligence (ai) technology or service company (the "target").

Multiple research studies are in official application stage for epw curesearch sites covering numerous protocols and specialties vancouver, bc / accesswire / july 31, 2023 / empower clinics inc (cse:epw)(otcqb:epwcf) ("empower" or the "company") a healthcare company with a developing research and clinical trials division is pleased to announce that its subsidiary epw curesearch llc ("epwc") has signed new agreements for additional pharmaceutical research and clinical trials medical doctors with an established pain management practice and includes two experienced principal investigators. in addition, the company announces epwc sites and principal investigators (pi's) are officially in application stage for multiple study protocols for diseases that include alzheimer's, autoimmune disorders, chronic obstructive pulmonary disease (copd), rheumatoid arthritis (ra), lupus and diabetes, as the current priorities.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said it has signed a letter of intent (LOI) with Crescita Capital LLC for a C$5 million equity capital facility. The capital facility is intended to be used for general working capital purposes, strategic business development and expansion of clinical trial assets.

Empower Clnincs Inc. has released a corporate update covering its developing research and clinical trials divisions.  Last month, Empower subsidiary EPW Curesearch LLC announced an agreement to develop a program for research and clinical trials services with a Dallas, Texas-based medical center.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) announced that it has signed another agreement for a principal investigator (PI) at its research and clinical trial site in Dallas, Texas.  This brings the number of experienced researchers at the site to four, paving the way for “conducting multiple research projects across a variety of specialties and disease states”, the healthcare company said.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said its subsidiary, EPW Curesearch LLC, has signed two new research services agreements with leading physicians and researchers to support clinical trials services at its first research site in Dallas, Texas. The additions bring the active count of professional investigators at the site to three and paves the way to conducting multiple research projects across a variety of specialties and disease states.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has announced an agreement to develop a program for research and clinical trials services with a Dallas, Texas-based medical center.  Under the deal, Empower subsidiary EPW Curesearch LLC (EPWC) will provide pharmaceutical research and clinical trial services, centralized project coordination and operations management, as well as access to technology and systems to support the services, and the provision of a sponsor contract for clinical trials services.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value with the engagement of Haywood Securities Inc as the company's strategic financial advisor. "Maximizing shareholder value is a priority and to that end, throughout late 2022 and during Q1 2023, Empower has been aggressively cutting costs and focusing its business lines and initiatives with the goal of accelerating our timeline to achieving profitability,” said Steven McAuley, chairman & CEO of Empower in a statement.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has said its previously announced LOI (letter of intent) to create and operate a Dallas-based Site Management Organization (SMO) has accelerated in the first 30 days with the official formation of a joint venture (JV) company in Delaware. The JV is a Delaware LLC between a US corporation owned by Empower (51%) and a Nevada LLC owned by Dr Mocherla (49%) formed together as EPW Curesearch, LLC.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has said it held $193,144 in cash at end-2022 as it announced its interim results for the fourth quarter to 31 December 2022.  The company has previously said it is changing its fiscal year end from December 31 to March 31.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said it has entered into a letter of intent (LOI) with Dr Bharat Mocherla, a Nuclear Medicine Specialist in Las Vegas, Nevada, with over 15 years of experience in the medical and clinical trials field, to create an operate a Dallas-based Site Management Organization (SMO) with plans to evolve into a Contract Research Organization (CRO). Empower said the proposed SMO is expected to work with industry, patients, community doctors and researchers in North America and globally to provide clinical trial management services for the pharmaceutical, biotechnology and medical device industries.

Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) told investors it signed a deal with PulseIR, a wholly-owned subsidiary of Fobi AI (TSX-V:FOBI, OTCQB:FOBIF), to deliver personalized, automated, and data-driven mobile investor relations (IR) solutions to existing and potential shareholders. The company explained that IR platforms must be able to fully deliver content and mobilization that public companies need to connect their stories, drive return on investment (ROI), and gain traction in a digital market.